ReviewInternational journal of medical sciences2007
Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout.
Review in International journal of medical sciences, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 127 citations in OpenAlex.
- Impact of Renal Impairment on the Pharmacodynamic and Pharmacokinetic Profiles of Epaminurad, a Novel Uric Acid Transporter 1 Inhibitor.Clinical and translational science · 2025Trial
- Trial
- Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout.Arthritis research & therapy · 2014Trial
- Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of HZBio1 in Chinese Healthy Subjects: A Randomized Phase 1a Study.Advances in therapy · 2026Article
- Effects of a Single Intramuscular Dose of Rasburicase on Plasma Uric Acid Concentrations in Fasted and Fed Ball Pythons (Veterinary sciences · 2026Article
- Serum uric acid and its metabolism-a vital factor in the inflammatory transformation of cancer.Journal of advanced research · 2026Review
- Drug-induced hyperuricemia: multi-pathway regulation, causative drugs, and individualized management strategies.Frontiers in pharmacology · 2026Review
- The role of Gln269Leu mutation on the thermostability and structure of uricase from Aspergillus flavus.Scientific reports · 2025Article
- The Gut-Kidney Axis in Uric Acid Nephropathy: Microbiota, Metabolic Crosstalk, and Translational Prospects.Journal of multidisciplinary healthcare · 2025Review
- Narrative literature review of antidiabetic drugs' effect on hyperuricemia: elaborating actual data and mechanisms.Endocrine connections · 2024Review
- Review
- Serum uric acid and high-sensitivity C-reactive protein levels among people living with HIV on dolutegravir and ritonavir-boosted atazanavir-based antiretroviral therapy: a comparative cross-sectional study.Frontiers in medicine · 2024Article
- U-shaped relationship between serum uric acid and gastric cancer risk: a large prospective cohort study.Frontiers in oncology · 2024Article
- An Updated Review For Hyperuricemia and Gout Management; Special Focus on the Available Drug Delivery Systems and Clinical Trials.Current medicinal chemistry · 2024Review
- Rasburicase-Induced Hemolytic Anemia Secondary to Undiagnosed G6PD Deficiency.Journal of Brown hospital medicine · 2023Article
- Gene Dose-Dependent and Additive Effects ofMetabolites · 2022Article
- Soluble uric acid inhibits β2 integrin-mediated neutrophil recruitment in innate immunity.Blood · 2022Article
- Enzyme Therapy: Current Challenges and Future Perspectives.International journal of molecular sciences · 2021Review
- The Effective Control of Hyperuricemia in Cancer Patients: A New Recombinant Conjugated Variant of Urate Oxidase.Asian Pacific journal of cancer prevention : APJCP · 2021Article
- Enzyme dynamics: Looking beyond a single structure.ChemCatChem · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hyperuricemia is a feature of several pathologies and requires an appropriate and often early treatment, owing to the severe consequences that it may cause. A rapid and massive raise of uric acid, during tumor lysis syndrome (TLS), and also a lower and chronic hyperuricemia, as in gout, mainly damage the kidney. To prevent or treat these consequences, a new therapeutic option is represented by rasburicase, a recombinant form of an enzyme, urate oxidase. This enzyme converts hypoxanthine and xanthine into allantoin, a more soluble molecule, easily cleared by kidney. The several types of urate oxidase have followed each other, with progressive reduction of adverse reactions. The most important among them are allergenicity and the development of antibodies which compromise their effectiveness. Nevertheless, a limit of rasburicase's use remains its cost, which obliges to a judicious choice to prevent TLS in high risk patients with cancer and in case of allergy or impossibility to take allopurinol orally both in TLS and in gout. A large body of evidence confirms the efficacy and safety of rasburicase, even in comparison to the standard drugs used in the aforementioned pathologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.